Published in Proc Natl Acad Sci U S A on September 02, 2005
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 4.52
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev (2006) 3.30
The Yin and Yang of HLA and KIR in human disease. Semin Immunol (2008) 2.72
HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 2.59
Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest (2010) 2.19
KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med (2009) 1.99
Comparative genomics of natural killer cell receptor gene clusters. PLoS Genet (2005) 1.85
Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A (2010) 1.72
Cytoskeletal stabilization of inhibitory interactions in immunologic synapses of mature human dendritic cells with natural killer cells. Blood (2011) 1.56
KIR-HLA intercourse in HIV disease. Trends Microbiol (2008) 1.55
Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol (2007) 1.43
Multiplicity and plasticity of natural killer cell signaling pathways. Blood (2005) 1.40
Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. PLoS Pathog (2006) 1.40
Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation. J Clin Invest (2013) 1.36
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32
Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood (2010) 1.30
Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology (2011) 1.28
Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun (2008) 1.28
KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol (2011) 1.26
Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. J Immunol (2010) 1.20
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
Primate-specific regulation of natural killer cells. J Med Primatol (2010) 1.14
Variable NK cell receptors exemplified by human KIR3DL1/S1. J Immunol (2011) 1.12
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol (2013) 1.10
Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. Blood (2006) 1.09
Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol (2011) 1.09
Innate immune control of HIV. Cold Spring Harb Perspect Med (2012) 1.09
Coevolution of killer cell Ig-like receptors with HLA-C to become the major variable regulators of human NK cells. J Immunol (2010) 1.09
Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One (2007) 1.09
Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics (2006) 1.07
Natural killer cell responses to viral infection. J Innate Immun (2011) 1.03
Extracellular domain alterations impact surface expression of stimulatory natural killer cell receptor KIR2DS5. Immunogenetics (2008) 1.03
TLR/NCR/KIR: Which One to Use and When? Front Immunol (2014) 1.03
Molecular recognition of paired receptors in the immune system. Front Microbiol (2012) 1.03
Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA. PLoS Pathog (2012) 1.02
HLA-Cw*0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog (2012) 1.01
Alterations in natural killer cell receptor profiles during HIV type 1 disease progression among chronically infected South African adults. AIDS Res Hum Retroviruses (2010) 1.01
Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies. Immunology (2009) 1.01
Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol (2012) 0.99
Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect (2012) 0.99
Here today--not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections. Eur J Immunol (2010) 0.98
NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol (2013) 0.97
Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia (2009) 0.97
Human diversity of killer cell immunoglobulin-like receptors and disease. Korean J Hematol (2011) 0.97
Activating killer cell Ig-like receptors in health and disease. Front Immunol (2014) 0.95
Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1. J Immunol (2011) 0.94
Natural killer cell responses to HIV-1 peptides are associated with more activating KIR genes and HLA-C genes of the C1 allotype. J Acquir Immune Defic Syndr (2011) 0.93
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One (2014) 0.92
Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1. J Virol (2015) 0.92
Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol (2009) 0.91
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica (2014) 0.91
In contrast to other stimulatory natural killer cell immunoglobulin-like receptor loci, several KIR2DS5 alleles predominate in African Americans. Hum Immunol (2009) 0.90
Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. Bone Marrow Transplant (2011) 0.89
Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function. AIDS (2014) 0.89
Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol (2009) 0.88
Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa. J Virol (2010) 0.87
Natural killer cells and their receptors in multiple sclerosis. Brain (2012) 0.87
The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology (2010) 0.87
Natural killer cells in immunodefense against infective agents. Expert Rev Anti Infect Ther (2008) 0.86
Chain-terminating natural mutations affect the function of activating KIR receptors 3DS1 and 2DS3. Immunogenetics (2007) 0.86
DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells. J Leukoc Biol (2013) 0.86
Structural insights into activation of antiviral NK cell responses. Immunol Rev (2012) 0.85
Innate immune responses against Epstein Barr virus infection. J Leukoc Biol (2013) 0.84
Complexity in cattle KIR genes: transcription and genome analysis. Immunogenetics (2007) 0.84
Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel) (2015) 0.84
Role of KIR3DS1 in human diseases. Front Immunol (2012) 0.83
An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia (2011) 0.83
Low CD4+ T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands. PLoS One (2011) 0.83
Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory? Front Immunol (2015) 0.83
Allelic variation of killer cell immunoglobulin-like receptor 2DS5 impacts glycosylation altering cell surface expression levels. Hum Immunol (2013) 0.82
Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol (2008) 0.82
An improved RT-PCR method for the detection of killer-cell immunoglobulin-like receptor (KIR) transcripts. Immunogenetics (2006) 0.81
Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates. Virology (2013) 0.81
Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis. Clin Exp Immunol (2010) 0.81
Modulation of Human Leukocyte Antigen-C by Human Cytomegalovirus Stimulates KIR2DS1 Recognition by Natural Killer Cells. Front Immunol (2017) 0.80
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition. Immunogenetics (2017) 0.80
Time to seroconversion in HIV-exposed subjects carrying protective versus non protective KIR3DS1/L1 and HLA-B genotypes. PLoS One (2014) 0.80
A study of KIR genes and HLA-C in Vogt-Koyanagi-Harada disease in Saudi Arabia. Mol Vis (2011) 0.80
Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3. PLoS Negl Trop Dis (2014) 0.80
Self-association of an activating natural killer cell receptor, KIR2DS1. PLoS One (2011) 0.80
Activating KIR2DS4 Is Expressed by Uterine NK Cells and Contributes to Successful Pregnancy. J Immunol (2016) 0.80
Missing or altered self: human NK cell receptors that recognize HLA-C. Immunogenetics (2017) 0.79
The Size of Activating and Inhibitory Killer Ig-like Receptor Nanoclusters Is Controlled by the Transmembrane Sequence and Affects Signaling. Cell Rep (2016) 0.79
Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles. J Immunol Res (2015) 0.79
KIR and HLA under pressure: evidences of coevolution across worldwide populations. Hum Genet (2015) 0.79
Killer cell immunoglobulin-like receptors in HLA-B27-associated acute anterior uveitis, with and without axial spondyloarthropathy. Invest Ophthalmol Vis Sci (2009) 0.79
Deciphering the KIR system at super-resolution for NK and T cell biology. Immunology (2016) 0.79
Killer immunoglobulin-like receptor gene repertoire influences viral load of primary human cytomegalovirus infection in renal transplant patients. Genes Immun (2014) 0.78
Cattle Ly49 is polymorphic. Immunogenetics (2009) 0.78
Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control. Front Immunol (2016) 0.77
Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells. Cancer Res (2016) 0.77
Association of killer cell immunoglobulin-like receptor and human leucocyte antigen-Cw gene combinations with systemic lupus erythematosus. Clin Exp Immunol (2015) 0.77
The early days of NK cells: an example of how a phenomenon led to detection of a novel immune receptor system - lessons from a rat model. Front Immunol (2014) 0.77
The role of NK cells in HIV-1 protection: autologous, allogeneic or both? AIDS Res Ther (2016) 0.77
KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients. Immunogenetics (2015) 0.76
The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands. Immunogenetics (2014) 0.76
NK cell recognition. Annu Rev Immunol (2005) 14.40
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002) 7.70
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 6.98
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 5.17
Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol (1979) 5.06
TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity (2004) 4.50
Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol (1986) 4.30
Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science (2001) 4.18
Natural killer cell signaling pathways. Science (2004) 4.00
Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet (2001) 3.96
Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med (2004) 3.87
Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature (2000) 3.54
Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol (2002) 3.45
Immune functions encoded by the natural killer gene complex. Nat Rev Immunol (2003) 3.21
Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol (1998) 2.79
Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med (1995) 2.75
NK cell and DC interactions. Trends Immunol (2004) 2.68
Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol (2001) 2.45
Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect (2002) 2.43
Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol (2001) 2.38
Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet (2005) 2.31
The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol (1992) 2.27
Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med (2005) 2.23
The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev (2002) 2.21
Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol (2004) 2.14
The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med (1997) 1.91
Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol (2004) 1.90
Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens (1983) 1.87
Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol (1997) 1.84
Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A (1998) 1.79
Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol (1995) 1.62
Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J Biol Chem (1999) 1.50
Understanding how combinations of HLA and KIR genes influence disease. J Exp Med (2005) 1.45
KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes (2003) 1.42
Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol (2004) 1.41
Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol (2001) 1.41
A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol (2002) 1.39
Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity (1998) 1.38
Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol (2004) 1.37
Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J Exp Med (2003) 1.22
MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol (2004) 1.22
Misfolding of major histocompatibility complex class I molecules in activated T cells allows cis-interactions with receptors and signaling molecules and is associated with tyrosine phosphorylation. J Biol Chem (2004) 1.18
HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest (1999) 1.18
Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4. J Immunol (2001) 1.15
Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol (2005) 1.11
Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J Immunol (2001) 0.96
Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines. Lab Invest (2002) 0.92
Recognition of infected cells by natural killer cells. Curr Opin Immunol (2004) 0.86
BIAcore analysis to test phosphopeptide-SH2 domain interactions. Methods Mol Biol (2000) 0.78
Functions of natural killer cells. Nat Immunol (2008) 9.88
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol (2008) 4.78
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Natural killer cell signaling pathways. Science (2004) 4.00
Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol (2008) 3.93
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Maturation of mouse NK cells is a 4-stage developmental program. Blood (2009) 3.31
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol (2002) 2.87
Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med (2007) 2.85
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
The trafficking of natural killer cells. Immunol Rev (2007) 2.62
Prevalence and seasonal variations of six bee viruses in Apis mellifera L. and Varroa destructor mite populations in France. Appl Environ Microbiol (2004) 2.56
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol (2009) 2.12
Germ-line and rearranged Tcrd transcription distinguish bona fide NK cells and NK-like gammadelta T cells. Eur J Immunol (2007) 2.11
Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity (2005) 2.08
Cutting edge: Priming of NK cells by IL-18. J Immunol (2008) 2.08
Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev (2008) 2.05
Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol (2005) 2.04
Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci U S A (2011) 2.01
Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol (2007) 2.00
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science (2012) 1.98
Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses. J Immunol (2011) 1.97
DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog (2007) 1.93
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92
Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature (2008) 1.88
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84
Killer immunoglobulin-like receptors. Curr Opin Immunol (2004) 1.83
The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (2003) 1.82
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol (2007) 1.78
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
Identity, regulation and in vivo function of gut NKp46+RORγt+ and NKp46+RORγt- lymphoid cells. EMBO J (2011) 1.74
Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med (2007) 1.73
The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol (2013) 1.72
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev (2006) 1.71
Dead or alive: deformed wing virus and Varroa destructor reduce the life span of winter honeybees. Appl Environ Microbiol (2011) 1.69
Predictive markers of honey bee colony collapse. PLoS One (2012) 1.68
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67
Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood (2007) 1.66
Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol (2007) 1.65
Protein kinase CK2 contributes to the organization of sodium channels in axonal membranes by regulating their interactions with ankyrin G. J Cell Biol (2008) 1.60
The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol (2003) 1.60
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood (2005) 1.57
In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol (2005) 1.57
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood (2008) 1.56
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol (2003) 1.55
What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 1.54
Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol (2004) 1.53